Myeloma patient preferences for treatments

This project was conducted between 2016-2017.

Aim of project

The aim of this study was to assess patient preferences for treatments, for example what attributes of a treatment are important.

Project summary

A survey was completed by 475 myeloma patients. In the survey, two hypothetical treatments were described and patients were asked to choose which treatment they would prefer. The descriptions of the hypothetical treatments in the survey focused on the following attributes: Mode and frequency of administration, out of pocket costs, average overall survival, remission period, and side effects. If patients did not think either hypothetical treatment was appropriate they had the option of choosing neither of the treatment options. The answers to these questions helped to identify which factors are most important to a patient when choosing between treatments.

The results of the survey showed that different treatment attributes were valued differently by different patients. However, overall the most important attribute was overall survival followed by remission period and the mode and frequency of treatment.

Who was involved with the project

This study was carried out by CaPPRe and 475 Myeloma patients completed the survey. A core steering committee including representation from Myeloma UK, myeloma patients, myeloma haematologists, and academics reviewed the project design and provided feedback.

How this project will help Myeloma patients

The data from this study can help us understand what matters most to patients when it comes to thinking about myeloma treatments. This type of information can help researchers decide what treatments to develop for myeloma patients in the future and help organisations like Myeloma UK campaign for access to treatments that patients think are valuable.

Acknowledgements and funding

This study was partially supported by a grant from Bristol Myers Squibb.


The results from this study have been published in the journal Patient Preference and Adherence.  You can read the published paper here.